Solid Tumor, Adult Clinical Trial
— HDAC6iOfficial title:
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours
Verified date | August 2020 |
Source | Karus Therapeutics Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to evaluate the safety/tolerability, pharmacokinetic, and
pharmaco-dynamic effects of KA2507 and establish the maximum tolerated dose (MTD). Patients
with PD-L1 expressing solid tumors which have relapsed or are refractory to prior treatment
will be eligible to participate in this study.
Following completion of the multiple ascending dose study, the protocol may be amended to
include expansion cohorts in patients with melanoma and/or other solid tumors.
Status | Completed |
Enrollment | 20 |
Est. completion date | June 10, 2020 |
Est. primary completion date | June 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age =18 years at the screening visit. 2. Patients with histologically or cytologically documented, confirmed diagnosis of advanced malignancy, whose disease failed to respond to or progressed after standard therapy or they could not tolerate standard therapy. 3. Measurable or evaluable disease according to RECIST v1.1. 4. ECOG performance status of 0 or 1. 5. Predicted life expectancy =12 weeks. 6. For men and women of child-bearing potential, willing to use adequate contraception (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study. 1. If female, must be either postmenopausal, sterilised or, if sexually active, effectively practicing an acceptable method of contraception (either oral, parenteral, or implantable hormonal contraceptives, intrauterine device or barrier and spermicide). Subjects must agree to use adequate contraception during the study and for at least 12 weeks (or longer as per local requirement) after the last dose of study treatment. 2. Male subjects agree to ensure that they or their female partner(s) use adequate contraception during the study and for at least 12 weeks (or longer as per local requirement) after the subject receives their last dose of study treatment. Exclusion Criteria: 1. Patients are not able to provide written informed consent to study participation 2. Patients who have been treated with most recent radiotherapy, hormonal therapy, immunotherapy, chemotherapy or investigational drugs within =21 days or 5 half-lives (whichever is shorter) from enrolment (screening), and/or who have any unresolved NCI Common Terminology Criteria of Adverse Events (CTCAE) v4.03 > Grade 1 treatment-related side effect (with the exception of alopecia). 3. Patient has anemia due to HbS or HbC disease, alpha or beta thalassaemia 4. Patient has Glucose-6-phosphate deficiency 5. Patient has known or suspected history of cytochrome b5-MetHb-reductase pathway deficiency 6. Persons of Navajo, Athabaska Alaskan or Siberian Yakutsk descent 7. Patient has untreated severe hypothyroidism 8. Patient has laboratory estimations indicating organ system dysfunction: 1. Absolute neutrophil count (ANC) <1.5 X 109/L 2. Platelets <100 X 109/L 3. Hemoglobin <9g/dL 4. Total bilirubin >1.5 mg/dL 5. ALT and AST >3.0 times the ULN if no liver involvement or >5 times the ULN with liver involvement. 6. Calculated creatinine clearance <60mL/min estimated using the Cockcroft-Gault equation: • Cockcroft-Gault equation: creatinine clearance = (140 - age in years) x (wt in kg)) x 1.23) / (serum creatinine in micromol/l) [For women multiply the result of calculation by 0.85]. 9. Major surgery (excluding placement of vascular access) =21 days from beginning of the study drug or minor surgical procedures =7 days. No waiting is required following implantable port and catheter placement. 10. Any of the following cardiac criteria: 1. Congestive heart failure (CHF), grade III or IV per New York Heart Association (NYHA) classification 2. Symptomatic cardiomyopathy 3. > Class II Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy 4. Unstable angina or new-onset angina 5. QTcF interval >470 ms on screening ECG. 9. Severe or uncontrolled systemic diseases including uncontrolled hypertension, active bleeding diatheses 10. Any evidence of active infection including active Hepatitis B, Hepatitis C or human immunodeficiency virus 11. The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease, uncontrolled hypertension, active bleeding diatheses). 12. Active infection requiring IV antibiotics within two weeks prior to treatment, or evidence of TB infection. 13. Hepatitis B, Hepatitis C or human immunodeficiency virus 14. Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 3 weeks previously and there is no evidence of central nervous system disease progression, mild neurologic symptoms, and no requirement for chronic corticosteroid therapy. 15. Lactating, breastfeeding, or positive pregnancy test for female patients of child-bearing potential. 16. The patient is unable to swallow capsules and/or has a surgical or anatomical condition that precludes swallowing and absorbing oral medication on an ongoing basis (for oral therapy only). 17. Patients with prior stem cell transplantation or solid organ transplantation. 18. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years. 17. Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Karus Therapeutics Limited |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Concentration of PD-L1 expression in tumor tissue | 24 weeks | ||
Other | Concentration of MHC-1 expression in tumor tissue | 24 weeks | ||
Primary | The occurrence of dose limiting toxicity | 1. Any event with possible or probable relationship to study drug occurring up to day 28 from the start of treatment as assessed using the National Cancers Institutes Common Terminology Criteria for Adverse events version 4.03 therapy. | 28 days | |
Secondary | Concentration of KA2507 in plasma over time (hours) post dosing | 24 weeks | ||
Secondary | Concentration of KA2507 in urine over time (hours) post dosing | 24 weeks | ||
Secondary | Blood concentration of histone acetylation during KA2507 treatment | 24 weeks | ||
Secondary | Blood concentration of tubulin during KA2507 treatment | 24 weeks | ||
Secondary | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment | 24 weeks | ||
Secondary | Clinical outcomes using the RECIST 1.1 criteria | 24 weeks | ||
Secondary | Clinical outcomes using Immuno-RECIST criteria | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04551885 -
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05054348 -
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT06088004 -
A Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04020185 -
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05071846 -
MVX-ONCO-2 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05607199 -
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
|
Phase 1 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Active, not recruiting |
NCT06026254 -
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
|
Phase 1 | |
Recruiting |
NCT06144671 -
GT201 Injection For The Treatment Of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06032845 -
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)
|
Phase 2 | |
Recruiting |
NCT05276284 -
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04121442 -
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04221204 -
A Monotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03992326 -
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05435339 -
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
Recruiting |
NCT06075849 -
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
|
Phase 1 | |
Recruiting |
NCT04092673 -
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
|
Phase 1/Phase 2 |